View in EDS HTML Full Text PDF Full Text

Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.

Saved in:
Bibliographic Details
Title: Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Authors: Lynce F; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Filipa_Lynce@dfci.harvard.edu.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. Filipa_Lynce@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. Filipa_Lynce@dfci.harvard.edu., Mainor C; MedStar Georgetown University Hospital, Washington, DC, USA., Donahue RN; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Geng X; Georgetown University, Washington, DC, USA., Jones G; NeoGenomics, Durham, NC, USA., Schlam I; MedStar Washington Hospital Center, Washington, DC, USA.; Tufts Medical Center, Boston, MA, USA., Wang H; Georgetown University, Washington, DC, USA., Toney NJ; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Jochems C; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Schlom J; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Zeck J; MedStar Georgetown University Hospital, Washington, DC, USA., Gallagher C; MedStar Washington Hospital Center, Washington, DC, USA., Nanda R; University of Chicago, Chicago, IL, USA., Graham D; Hackensack University Medical Center, Hackensack, NJ, USA., Stringer-Reasor EM; University of Alabama at Birmingham, Birmingham, AL, USA., Denduluri N; AstraZeneca, Arlington, VA, USA., Collins J; MedStar Georgetown University Hospital, Washington, DC, USA.; AstraZeneca, Arlington, VA, USA., Chitalia A; MedStar Washington Hospital Center, Washington, DC, USA., Tiwari S; MedStar Washington Hospital Center, Washington, DC, USA., Nunes R; Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, USA.; AstraZeneca, Arlington, VA, USA., Kaltman R; Inova, Fairfax, VA, USA., Khoury K; University of Alabama at Birmingham, Birmingham, AL, USA., Gatti-Mays M; The Ohio State University, Columbus, OH, USA., Tarantino P; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Tolaney SM; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Swain SM; Georgetown University, Washington, DC, USA., Pohlmann P; MedStar Georgetown University Hospital, Washington, DC, USA., Parsons HA; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Isaacs C; Georgetown University, Washington, DC, USA.
Source: Nature communications [Nat Commun] 2024 May 10; Vol. 15 (1), pp. 3957. Date of Electronic Publication: 2024 May 10.
Publication Type: Published Erratum
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE; PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38730268
AccessLevel: 2
PubTypeId: unknown
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lynce+F%22">Lynce F</searchLink>; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Filipa_Lynce@dfci.harvard.edu.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. Filipa_Lynce@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. Filipa_Lynce@dfci.harvard.edu.<br /><searchLink fieldCode="AU" term="%22Mainor+C%22">Mainor C</searchLink>; MedStar Georgetown University Hospital, Washington, DC, USA.<br /><searchLink fieldCode="AU" term="%22Donahue+RN%22">Donahue RN</searchLink>; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Geng+X%22">Geng X</searchLink>; Georgetown University, Washington, DC, USA.<br /><searchLink fieldCode="AU" term="%22Jones+G%22">Jones G</searchLink>; NeoGenomics, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Schlam+I%22">Schlam I</searchLink>; MedStar Washington Hospital Center, Washington, DC, USA.; Tufts Medical Center, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Wang+H%22">Wang H</searchLink>; Georgetown University, Washington, DC, USA.<br /><searchLink fieldCode="AU" term="%22Toney+NJ%22">Toney NJ</searchLink>; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Jochems+C%22">Jochems C</searchLink>; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Schlom+J%22">Schlom J</searchLink>; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Zeck+J%22">Zeck J</searchLink>; MedStar Georgetown University Hospital, Washington, DC, USA.<br /><searchLink fieldCode="AU" term="%22Gallagher+C%22">Gallagher C</searchLink>; MedStar Washington Hospital Center, Washington, DC, USA.<br /><searchLink fieldCode="AU" term="%22Nanda+R%22">Nanda R</searchLink>; University of Chicago, Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Graham+D%22">Graham D</searchLink>; Hackensack University Medical Center, Hackensack, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Stringer-Reasor+EM%22">Stringer-Reasor EM</searchLink>; University of Alabama at Birmingham, Birmingham, AL, USA.<br /><searchLink fieldCode="AU" term="%22Denduluri+N%22">Denduluri N</searchLink>; AstraZeneca, Arlington, VA, USA.<br /><searchLink fieldCode="AU" term="%22Collins+J%22">Collins J</searchLink>; MedStar Georgetown University Hospital, Washington, DC, USA.; AstraZeneca, Arlington, VA, USA.<br /><searchLink fieldCode="AU" term="%22Chitalia+A%22">Chitalia A</searchLink>; MedStar Washington Hospital Center, Washington, DC, USA.<br /><searchLink fieldCode="AU" term="%22Tiwari+S%22">Tiwari S</searchLink>; MedStar Washington Hospital Center, Washington, DC, USA.<br /><searchLink fieldCode="AU" term="%22Nunes+R%22">Nunes R</searchLink>; Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, USA.; AstraZeneca, Arlington, VA, USA.<br /><searchLink fieldCode="AU" term="%22Kaltman+R%22">Kaltman R</searchLink>; Inova, Fairfax, VA, USA.<br /><searchLink fieldCode="AU" term="%22Khoury+K%22">Khoury K</searchLink>; University of Alabama at Birmingham, Birmingham, AL, USA.<br /><searchLink fieldCode="AU" term="%22Gatti-Mays+M%22">Gatti-Mays M</searchLink>; The Ohio State University, Columbus, OH, USA.<br /><searchLink fieldCode="AU" term="%22Tarantino+P%22">Tarantino P</searchLink>; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Tolaney+SM%22">Tolaney SM</searchLink>; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Swain+SM%22">Swain SM</searchLink>; Georgetown University, Washington, DC, USA.<br /><searchLink fieldCode="AU" term="%22Pohlmann+P%22">Pohlmann P</searchLink>; MedStar Georgetown University Hospital, Washington, DC, USA.<br /><searchLink fieldCode="AU" term="%22Parsons+HA%22">Parsons HA</searchLink>; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Isaacs+C%22">Isaacs C</searchLink>; Georgetown University, Washington, DC, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101528555%22">Nature communications</searchLink> [Nat Commun] 2024 May 10; Vol. 15 (1), pp. 3957. <i>Date of Electronic Publication: </i>2024 May 10.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Published Erratum
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101528555 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-1723 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220411723%22">20411723 </searchLink><i>NLM ISO Abbreviation: </i>Nat Commun <i>Subsets: </i>MEDLINE; PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38730268
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41467-024-48359-1
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3957
    Titles:
      – TitleFull: Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lynce F
      – PersonEntity:
          Name:
            NameFull: Mainor C
      – PersonEntity:
          Name:
            NameFull: Donahue RN
      – PersonEntity:
          Name:
            NameFull: Geng X
      – PersonEntity:
          Name:
            NameFull: Jones G
      – PersonEntity:
          Name:
            NameFull: Schlam I
      – PersonEntity:
          Name:
            NameFull: Wang H
      – PersonEntity:
          Name:
            NameFull: Toney NJ
      – PersonEntity:
          Name:
            NameFull: Jochems C
      – PersonEntity:
          Name:
            NameFull: Schlom J
      – PersonEntity:
          Name:
            NameFull: Zeck J
      – PersonEntity:
          Name:
            NameFull: Gallagher C
      – PersonEntity:
          Name:
            NameFull: Nanda R
      – PersonEntity:
          Name:
            NameFull: Graham D
      – PersonEntity:
          Name:
            NameFull: Stringer-Reasor EM
      – PersonEntity:
          Name:
            NameFull: Denduluri N
      – PersonEntity:
          Name:
            NameFull: Collins J
      – PersonEntity:
          Name:
            NameFull: Chitalia A
      – PersonEntity:
          Name:
            NameFull: Tiwari S
      – PersonEntity:
          Name:
            NameFull: Nunes R
      – PersonEntity:
          Name:
            NameFull: Kaltman R
      – PersonEntity:
          Name:
            NameFull: Khoury K
      – PersonEntity:
          Name:
            NameFull: Gatti-Mays M
      – PersonEntity:
          Name:
            NameFull: Tarantino P
      – PersonEntity:
          Name:
            NameFull: Tolaney SM
      – PersonEntity:
          Name:
            NameFull: Swain SM
      – PersonEntity:
          Name:
            NameFull: Pohlmann P
      – PersonEntity:
          Name:
            NameFull: Parsons HA
      – PersonEntity:
          Name:
            NameFull: Isaacs C
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 10
              M: 05
              Text: 2024 May 10
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 2041-1723
          Numbering:
            – Type: volume
              Value: 15
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Nature communications
              Type: main
ResultId 1